|
Nimotuzumab for the treatment of high grade of malignancy tumors |
2013-02-01 |
CIMAB |
|
Nimotuzumab cold kit for the immunodiagnosis of solid tumors |
05/10/2018 |
CIM |
|
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer |
28/11/2016 |
CIM |
|
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer |
12/10/2016 |
CIM |
|
NeuroEPO-Stroke. Phase I-II |
11/09/2014 |
CIMAB |
|
NeuroEPO-Ataxia-Adults-Phase III |
19/11/2020 |
CIM |
|
NeuroEPO – Type 2 Spinocerebellar Ataxia Phase I-II |
02/11/2014 |
CIMAB |
|
NeuroEPO in mild-moderate Alzheimer's disease amnesic variant |
22/09/2022 |
CIM |
|
NASVAC Phase II Trial in patients with Chronic Hepatitis B Virus infection |
2012-10-12 |
CIGB |
|
Nasalferon in respiratory infections in adults. Phase 3 clinical trial. |
13/02/2025 |
CIGB |
|
Nasalferon in ARI |
29/07/2022 |
CIGB |
|
Nasal recombinant human interferon alfa-2b in ARI |
06/12/2022 |
CIGB |
|
Melagenina Plus - Vitiligo – phase IV |
14/01/2019 |
CHP |
|
MAMBISA Study |
26/11/2020 |
CIGB |
|
Lithium Carbonate-COVID-19- mild and moderate -Exploratory / Phase II |
05/08/2021 |
ICBPGirón |
|
Kardioli® nutritional supplement versus placebo in patients with chronic heart failure. Phase II. |
03/03/2023 |
CATALYSIS |
|
Jusvinza in Severe Patients with Acquired Community Pneumonia |
14/10/2022 |
CIGB |
|
Jusvinza in rheumatoid arthritis |
20/04/2022 |
CIGB |
|
Itolizumab-Plasmapheresis in patients with COVID-19 |
30/06/2021 |
CIM |
|
Itolizumab Safety and Efficacy Study in Covid 19 |
26/03/2021 |
CIM |
